References

  1. World Health Organization. Global tuberculosis report. 2014. Google Scholar

  2. Claude Mambo Muvunyi and Florence Masaisa. Diagnosis of Smear-Negative Pulmonary Tuberculosis in low-income countries: current Evidence in Sub-Saharan Africa with Special Focus on HIV Infection. 2012. Google Scholar

  3. Nakiyingi L, Bwanika JM, Kirenga B, Nakanjako D, Katabira C et al. Clinical Predictors and Accuracy of Empiric Tuberculosis Treatment among Sputum Smear-Negative HIV-Infected Adult TB Suspects in Uganda. PLoS ONE. 2013; 8(9): e74023. PubMed | Google Scholar

  4. Lawn SD, Ayles H, Egwaga S, Williams B, Mukadi YD, Santos Filho ED, Godfrey-Faussett P, Granich RM, Harries AD. Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings. Int J Tuberc Lung Dis. 2011 Mar; 15(3): 287-95. PubMed | Google Scholar

  5. World Health Organization. Monitoring of Xpert MTB/RIF roll-out. Available at http://who.int/tb/laboratory/mtbrifrollout. Accessed Feb 2 2014. Google Scholar

  6. WHO. Policy Statement on Xpert MTB-RIF, Update. 2014. http://tbevidence.org/wp-content/uploads/2014/04/WHO-Xpert-Policy-Update.pdf. Accessed Mar-20-2015. Google Scholar

  7. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014 Jan 21; 1: CD009593. PubMed | Google Scholar

  8. Walusimbi S, Bwanga F, De Costa A, Haile M, Joloba M, Hoffner S. Meta-analysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis. BMC Infect Dis. 2013 Oct 30; 13: 507. PubMed | Google Scholar

  9. WHO. Xpert MTB/RIF implementation manual. 2014. http://tbevidence.org/wp-content/uploads/2014/04/Xpert-implementation-Manual-2014.pdf. Accessed Mar-10-2015. Google Scholar

  10. Schnippel K, Meyer-Rath G, Long L, Stevens WS, Sanne I, Rosen S. Diagnosing Xpert MTB/RIF-negative TB: impact and cost of alternative algorithms for South Africa. S Afr Med J. 2013; 103(2): 101-106. PubMed | Google Scholar

  11. Alamo ST, Kunutsor S, Walley J, Thoulass J, Evans M, Muchuro S, Matovu A, Katabira E. Performance of the new WHO diagnostic algorithm for smear-negative pulmonary tuberculosis in HIV prevalent settings: a multisite study in Uganda. Trop Med Int Health. 2012; 17(7): 884-895. PubMed | Google Scholar

  12. Wekesa C, Kirenga BJ, Joloba ML, Bwanga F, Katamba A, Kamya MR. Chest X-ray vs. Xpert® MTB/RIF assay for the diagnosis of sputum smear-negative tuberculosis in Uganda. Int J Tuberc Lung Dis. 2014; 18(2): 216-219. PubMed | Google Scholar

  13. Stall N, Rubin T, Michael JS, Mathai D, Abraham OC, Mathews P, Thomas K, John M, Daley P. Does solid culture for tuberculosis influence clinical decision making in India? Int J Tuberc Lung Dis. 2011 May; 15(5): 641-6. PubMed | Google Scholar

  14. Schnippel K, Meyer-Rath G, Long L, MacLeod W, Sanne I, Stevens WS, Rosen S. Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop Med Int Health. 2012; 17(9):1142-1151. PubMed | Google Scholar

  15. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2014 Feb 1; 383(9915): 424-35. PubMed | Google Scholar

  16. Hanrahan CF, Selibas K, Deery CB, Dansey H, Clouse K et al. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care Xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS ONE. 2013; 8(6): e65421. PubMed | Google Scholar

  17. WHO: Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings. In. Geneva; 2007. Google Scholar

  18. Published evidence and commentary on the Xpert MTB/RIF assay. Updated 12, March 2014. http://www.stoptb.org/wg/gli/assets/documents/map/XpertPublications.pdf. Accessed Mar-14-2015. Google Scholar

  19. Wilkinson D, Newman W, Reid A, Squire SB, Sturm AW, Gilks CF. Trial-of-antibiotic algorithm for the diagnosis of tuberculosis in a district hospital in a developing country with high HIV prevalence. Int J Tuberc Lung Dis. 2000 Jun; 4(6): 513-8. PubMed | Google Scholar

  20. Walusimbi S, Bwanga F, Costa AD, Haile M, Hoffner S, Joloba M. Evaluation of the Xpert MTB/Rif test, microscopic observation drug susceptibility test and nitrate reductase assay, for rapid and accurate diagnosis of smear-negative tuberculosis in HIV patients. Int J Mycobacteriol. 2013 Sep; 2(3): 148-55. PubMed | Google Scholar

  21. Stephen Lawn D, Andrew Kerkhoff D, Monica Vogt, Yonas Ghebrekristos, Andrew Whitelaw, Robin Wood. Characteristics and early outcomes of patients with xpert mtb/rif-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin Infect Dis. 2012; 54(8): 1071-1079. PubMed | Google Scholar

  22. WHO: Laboratory services in tuberculosis control culture. Part III. Geneva: Switzerland. In: Culture examination and identification. WHO/TB/98.258. edn; 1998. Google Scholar

  23. Brian Bell G, Francois Schellevis, Ellen Stobberingh HG, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis. 2014 Jan 9; 14: 13. PubMed | Google Scholar

  24. Sanjay Jain K, Bishai WR. Adherence to therapy, treatment success, and prevention of resistance. Infectious Dis Clin Pract. 2006; 14(4): S15-S18. PubMed | Google Scholar

  25. Tun-Chieh Chen, Po-Liang Lu, Chun-Yu Lin, Wei-Ru Lin, Chen Y-H. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. International Journal of Infectious Diseases. 2011; 15: e211-e216. PubMed | Google Scholar

  26. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H et al. Antibiotic resistance-the need for global solutions. The Lancet Infectious diseases. 2013; 13(12): 1057-1098. PubMed | Google Scholar

  27. Okwera A, Bwanga F, Najjingo I, Mulumba Y, Mafigiri DK, Whalen CC, Joloba ML. Aetiology of pulmonary symptoms in HIV-infected smear negative recurrent PTB suspects in Kampala, Uganda: a cross-sectional study. PloS one. 2013; 8(12): e82257. PubMed | Google Scholar

  28. Ginsburg AS, Tinkham L, Riley K, Kay NA, Klugman KP, Gill CJ. Antibiotic non-susceptibility among Streptococcus pneumoniae and Haemophilus influenzae isolates identified in African cohorts: a meta-analysis of three decades of published studies. International journal of antimicrobial agents. 2013; 42(6): 482-491. PubMed | Google Scholar

  29. Huerga H, Varaine F, Okwaro E, Bastard M, Ardizzoni E, Sitienei J, Chakaya J, Bonnet M. Performance of the 2007 WHO algorithm to diagnose smear-negative pulmonary tuberculosis in a HIV prevalent setting. PloS one. 2012; 7(12): e51336. PubMed | Google Scholar

  30. Uganda AIDS Commission. Global AIDS response progress report. April 2012. Available at: Http://www.Unaids.Org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/. Accessed Nov-10-2014. Google Scholar